Key Developments: Oragenics Inc (OGEN.A)

OGEN.A on American Stock Exchange

1.69USD
21 Aug 2014
Price Change (% chg)

$0.03 (+1.81%)
Prev Close
$1.66
Open
$1.69
Day's High
$1.69
Day's Low
$1.69
Volume
102
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Oragenics Inc Announces Completion Of Public Offering Of Common Stock
Wednesday, 20 Nov 2013 12:22pm EST 

Oragenics, Inc announced that it has completed its previously announced underwritten public offering of 4,400,000 shares of common stock at a public offering price of $2.50 per share. The net proceeds to the Company, after underwriting discounts and commissions and estimated offering expenses, were $9,847,500. Griffin Securities was the sole underwriter for the offering.  Full Article

Oragenics Inc Prices Public Offering of Common Stock
Friday, 15 Nov 2013 09:29am EST 

Oragenics, Inc announced that it has priced an underwritten public offering of 4,400,000 shares of its common stock at a public offering price of $2.50 per share for aggregate gross proceeds of $11.0 million, prior to underwriting discounts and offering expenses. The offering is expected to close on or about November 20 2013, subject to satisfaction of customary closing conditions. Griffin Securities, Inc. is acting as underwriter for the offering.  Full Article

Oragenics Inc Announces Proposed Public Offering of Common Stock
Thursday, 14 Nov 2013 06:32pm EST 

Oragenics Inc announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by Oragenics. Griffin Securities, Inc. is acting as sole underwriter for the proposed offering on a firm commitment basis. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Oragenics intends to use the net proceeds from the public offering for continued development of its lantibiotics program and for general corporate and working capital purposes.  Full Article

Oragenics Inc Receives First European Patent For ProBiora3 Probiotic Blend
Tuesday, 12 Mar 2013 09:23am EDT 

Oragenics Inc announced it has received its first patent approval in Europe for its ProBiora3 products. The approval provides additional protection for ProBiora3`s blend of three probiotic bacteria, specifically designed to enhance oral health, whiten teeth and freshen breath. ProBiora3 is currently being sold under the brand name Evora in the U.S. and in over 13 countries around the world. European Patent No. 1659885, entitled Compositions and Methods for the Maintenance of Oral Health, affords protection for ProBiora3 for use in a broad spectrum of applications, including the prevention of tooth decay and periodontal diseases, halitosis, and other therapeutic and cosmetic applications. The claims further protect ProBiora3 in several delivery forms, such as food supplements, tablets, and mouth rinses.  Full Article

Oragenics Inc Announces Strategic Partnership With Organic Wave, Inc.
Tuesday, 22 Jan 2013 08:15am EST 

Oragenics Inc announced that the Company has entered into a new three year contract agreement with Organic Wave, Inc. Under the terms of the agreement, Organic Wave will be the exclusive distributor of Oragenics` oral care probiotics for pets in Japan under the Evora name as well as a private label brand. The pet product will contain ProBiora3; Oragenics` patented proprietary blend of three probiotics specifically designed for improved oral health.  Full Article

Search Stocks